DB:AM6

Stock Analysis Report

Executive Summary

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare metabolic diseases.

Rewards

Trading at 82.3% below its fair value

Revenue is forecast to grow 36.69% per year

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year



Snowflake Analysis

Excellent balance sheet and slightly overvalued.


Similar Companies

Share Price & News

How has Amicus Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AM6 has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-2.5%

AM6

0.4%

DE Biotechs

0.2%

DE Market


1 Year Return

-1.8%

AM6

9.0%

DE Biotechs

14.4%

DE Market

Return vs Industry: AM6 underperformed the German Biotechs industry which returned 9% over the past year.

Return vs Market: AM6 underperformed the German Market which returned 14.4% over the past year.


Shareholder returns

AM6IndustryMarket
7 Day-2.5%0.4%0.2%
30 Day6.5%-2.1%0.9%
90 Day15.2%8.0%4.6%
1 Year-1.8%-1.8%9.2%9.0%17.9%14.4%
3 Year75.8%75.8%45.5%43.9%15.7%5.6%
5 Year33.2%33.2%12.8%10.5%23.4%6.5%

Price Volatility Vs. Market

How volatile is Amicus Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Amicus Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: AM6 (€9.85) is trading below our estimate of fair value (€55.65)

Significantly Below Fair Value: AM6 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: AM6 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: AM6 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AM6's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AM6 is overvalued based on its PB Ratio (5x) compared to the DE Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Amicus Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

50.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AM6 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AM6 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AM6 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AM6's revenue (36.7% per year) is forecast to grow faster than the German market (5% per year).

High Growth Revenue: AM6's revenue (36.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: AM6 is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Amicus Therapeutics performed over the past 5 years?

-32.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AM6 is currently unprofitable.

Growing Profit Margin: AM6 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AM6 is unprofitable, and losses have increased over the past 5 years at a rate of -32.4% per year.

Accelerating Growth: Unable to compare AM6's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AM6 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: AM6 has a negative Return on Equity (-62.88%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Amicus Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: AM6's short term assets ($576.7M) exceed its short term liabilities ($93.1M).

Long Term Liabilities: AM6's short term assets ($576.7M) exceed its long term liabilities ($240.9M).


Debt to Equity History and Analysis

Debt Level: AM6's debt to equity ratio (27.2%) is considered satisfactory.

Reducing Debt: AM6's debt to equity ratio has reduced from 32.4% to 27.2% over the past 5 years.


Balance Sheet

Inventory Level: AM6 has a low level of unsold assets or inventory.

Debt Coverage by Assets: AM6's debt is covered by short term assets (assets are 3.9x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AM6 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if AM6 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Amicus Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.6%industryaverage1.0%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate AM6's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate AM6's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AM6's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AM6's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AM6's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.5yrs

Average management tenure


CEO

John Crowley (52yo)

8.5yrs

Tenure

US$7,419,963

Compensation

Mr. John F. Crowley has been the Chairman of Amicus Therapeutics, Inc. since February 2010 and has been its Chief Executive Officer since August 15, 2011. Mr. Crowley served as the Chief Executive Officer  ...


CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD7.42M) is above average for companies of similar size in the German market ($USD2.18M).

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
John Crowley
Chairman & CEO8.5yrsUS$7.42m0.39% $9.9m
Bradley Campbell
President1.7yrsUS$2.83m0.14% $3.6m
Ellen Rosenberg
Chief Legal Officer & Corporate Secretary4yrsUS$2.08m0.079% $2.0m
Jay Barth
Chief Medical Officer5.9yrsUS$2.09m0.061% $1.6m
Daphne Quimi
Chief Financial Officer1.1yrsUS$325.40k0.075% $1.9m
Samantha Prout
Global Controller & Principal Accounting Officer1.7yrsno data0.0024% $62.1k
Enrique Diloné
Senior Vice President of Technical Operations0yrsno datano data
Hung Do
Chief Scientific Officer4.6yrsUS$1.27m0.20% $5.1m
Sara Pellegrino
Vice President of Investor Relations & Corporate Communications0yrsno datano data
Patrik Florencio
Senior VP4.5yrsno datano data

4.5yrs

Average Tenure

52yo

Average Age

Experienced Management: AM6's management team is considered experienced (4.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
John Crowley
Chairman & CEO8.5yrsUS$7.42m0.39% $9.9m
Bradley Campbell
President1.7yrsUS$2.83m0.14% $3.6m
Robert Essner
Independent Director7.7yrsUS$199.71k0.0035% $88.9k
Burke Whitman
Independent Director0.7yrsno data0.0019% $49.4k
Glenn Sblendorio
Independent Director13.7yrsUS$219.71k0.0086% $218.2k
Margaret McGlynn
Independent Director10.3yrsUS$217.21k0.0074% $188.9k
Ted Love
Independent Director7.7yrsUS$209.71k0.059% $1.5m
Craig Wheeler
Independent Director3.7yrsUS$204.71k0.0035% $88.9k
Michael Raab
Lead Independent Director1.4yrsUS$257.27k0.0035% $88.9k
Lynn Bleil
Independent Director1.4yrsUS$257.49kno data

5.7yrs

Average Tenure

59.5yo

Average Age

Experienced Board: AM6's board of directors are considered experienced (5.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 24.4%.


Top Shareholders

Company Information

Amicus Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Amicus Therapeutics, Inc.
  • Ticker: AM6
  • Exchange: DB
  • Founded: 2002
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$2.754b
  • Listing Market Cap: US$2.546b
  • Shares outstanding: 254.81m
  • Website: https://www.amicusrx.com

Number of Employees


Location

  • Amicus Therapeutics, Inc.
  • 1 Cedar Brook Drive
  • Cranbury
  • New Jersey
  • 8512
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
FOLDNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDMay 2007
AM6DB (Deutsche Boerse AG)YesCommon StockDEEURMay 2007
0HF9LSE (London Stock Exchange)YesCommon StockGBUSDMay 2007

Biography

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare metabolic diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 1/2 (ATB200-02) and Phase 3 (ATB200-03) clinical studies for an investigational enzyme replacement therapy (AT-GAA) for Pompe disease. The company has a research and development collaboration with the University of Pennsylvania to develop AAV gene therapies; and a strategic manufacturing agreement with Catalent Biologics. The company also has a strategic manufacturing collaboration with Thermo Fisher Scientific for conducting preclinical and clinical-stage gene therapy programs for CLN6, CLN3, and other Batten disease programs. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/19 21:47
End of Day Share Price2020/02/19 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.